AXON Axovant Sciences Ltd.

24.27
+1.39  (6%)
Previous Close 22.88
Open 23.06
Price To book 12.64
Market Cap 2609654200
Shares 107,525,925
Volume 1,265,212
Short Ratio 5.83
Av. Daily Volume 656,307

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1Q 2018.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data due 4Q 2017
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due 4Q 2017.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data are due late September 2017.
Intepirdine - MINDSET
Alzheimer's disease